Stockscreener 앱 받기
0.1743
0.85%
-0.0015
Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스
What Did We Find About Insider Trading At Syros Pharmaceuticals Inc (NASDAQ: SYRS)? - Stocks Register
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.17, Down -3.99 - The Dwinnex
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Now Carries A 12-Month Price Target Of $5. - Marketing Sentinel
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Syros Pharmaceuticals Inc [NASDAQ: SYRS] Sees Increase in Stock Value - Knox Daily
Check Out Syros Pharmaceuticals Inc (SYRS)’s Trade Data Rather Than the Analysts’ Views - SETE News
Syros Pharmaceuticals Inc (SYRS) Stock Price and Analyst Predictions - The News Heater
H.C. Wainwright Upgrades Syros Pharmaceuticals Inc (SYRS) to a Buy from a Neutral - Knox Daily
Ratio Examination: Syros Pharmaceuticals Inc (SYRS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Fell -2280.95%, Predicting What To Expect In The Near Future - Marketing Sentinel
SYRS News Today | Why did Syros Pharmaceuticals stock go down today? - MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com - Defense World
Analysts’ Revisions Show Improving Sentiment For Syros Pharmaceuticals Inc (NASDAQ: SYRS) - Stocks Register
Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listi - Defense World
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Syros Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
November's phase III successes; Syros, Cassava tumble on misses - BioWorld Online
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com India
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - The Eastern Progress Online
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 - Investing.com
Syros Pharmaceuticals (LTS:0LC7) Enterprise Value : $8.13 Mil (As of Jan. 03, 2025) - GuruFocus.com
SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
0.27%
3.05%
자본화:
|
볼륨(24시간):